Sustaining Innovation Analyst Day

IR thematic call on sarilumab

Sanofi and Regeneron hosted a conference call for the financial community on sarilumab during the American College of Rheumatology Annual (ACR) Meeting in San Francisco.

Sarilumab is a fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R). This investigational compound is currently in clinical development for Rheumatoid Arthritis. Sarilumab achieved primary efficacy endpoints across all completed pivotal Phase 3 studies, including for TARGET and ASCERTAIN. Data from these two studies were presented as oral presentations at ACR on November 8th.

Related press releases

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies